Search results
Showing 526 to 540 of 2575 results for methods
In development Reference number: GID-TA11812 Expected publication date: TBC
Awaiting development Reference number: GID-TA11878 Expected publication date: TBC
In development Reference number: GID-TA11869 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 19 February 2026.
In development Reference number: GID-TA11776 Expected publication date: TBC
Evidence-based recommendations on gefitinib (Iressa) for untreated locally advanced or metastatic non-small-cell lung cancer in adults.
This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.
View quality statements for QS178Show all sections
Sections for QS178
- Quality statements
- Quality statement 1: Asking people about their sexual history
- Quality statement 2: Discussing prevention and testing with people who are at risk of sexually transmitted infections
- Quality statement 3: Condom distribution schemes
- Quality statement 4: Access to sexual health services
- Quality statement 5: Repeat testing for sexually transmitted infections
- Quality statement 6: Partner notification
- Update information
This quality standard covers assessing and treating fertility problems in people with explained and unexplained infertility, including access to IVF treatment. It also covers cryopreservation before cancer treatment that may affect fertility. It describes high-quality care in priority areas for improvement.
View quality statements for QS73Show all sections
Sections for QS73
- List of quality statements
- Quality statement 1: Lifestyle advice
- Quality statement 2: Referral for specialist consultation
- Quality statement 3: Counselling
- Quality statement 4: Semen analysis
- Quality statement 5: IVF for women under 40 years
- Quality statement 6: IVF for women aged 40 to 42 years
- Quality statement 7: Intracytoplasmic sperm injection
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Awaiting development Reference number: GID-TA10553 Expected publication date: TBC
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]
In development Reference number: GID-TA11759 Expected publication date: TBC
Awaiting development Reference number: GID-TA10393 Expected publication date: TBC
In development Reference number: GID-TA11657 Expected publication date: 07 April 2027
In development Reference number: GID-TA11813 Expected publication date: TBC
Nipocalimab for treating generalised myasthenia gravis [ID6562]
In development Reference number: GID-TA11492 Expected publication date: TBC
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]
In development Reference number: GID-TA11036 Expected publication date: TBC